株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Hyundai Pharmaceutical Co., Ltd.の製品パイプライン分析

Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 319978
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
Hyundai Pharmaceutical Co., Ltd.の製品パイプライン分析 Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016
出版日: 2016年12月30日 ページ情報: 英文 42 Pages
概要

Hyundai Pharmaceutical Co., Ltd.は韓国に本社をもつ製薬企業です。ファーマシューティカル製品や健康食品・飲料、医療機器などの製造・販売を行っています。

当レポートでは、Hyundai Pharmaceutical Co., Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Hyundai Pharmaceutical Co., Ltd.の基本情報

  • Hyundai Pharmaceutical Co., Ltd.の概要
  • 主要情報
  • 企業情報

Hyundai Pharmaceutical Co., Ltd.:R&Dの概要

  • 主な治療範囲

Hyundai Pharmaceutical Co., Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Hyundai Pharmaceutical Co., Ltd.:パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

Hyundai Pharmaceutical Co., Ltd.:薬剤プロファイル

  • NZ-419
  • choline alfoscerate SR
  • HOB-048
  • HOB-051
  • HD-0471042
  • HD-0471953
  • UHC-1
  • HOB-046
  • HOB-047

Hyundai Pharmaceutical Co., Ltd.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Hyundai Pharmaceutical Co., Ltd.:開発休止中のプロジェクト

Hyundai Pharmaceutical Co., Ltd.:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08176CDB

Summary

Global Markets Direct's, 'Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016', provides an overview of the Hyundai Pharmaceutical Co Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Hyundai Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Hyundai Pharmaceutical Co Ltd
  • The report provides overview of Hyundai Pharmaceutical Co Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Hyundai Pharmaceutical Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Hyundai Pharmaceutical Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Hyundai Pharmaceutical Co Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hyundai Pharmaceutical Co Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hyundai Pharmaceutical Co Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyundai Pharmaceutical Co Ltd Snapshot
    • Hyundai Pharmaceutical Co Ltd Overview
    • Key Facts
  • Hyundai Pharmaceutical Co Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Hyundai Pharmaceutical Co Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Hyundai Pharmaceutical Co Ltd - Pipeline Products Glance
    • Hyundai Pharmaceutical Co Ltd - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Hyundai Pharmaceutical Co Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Hyundai Pharmaceutical Co Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Hyundai Pharmaceutical Co Ltd - Drug Profiles
    • BPS-015 SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • choline alfoscerate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HD-0471042 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HD-0471953 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HD-6277 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-060 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-071 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-075 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTB-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTB-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levodropropizine CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tranexamic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UHC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hyundai Pharmaceutical Co Ltd - Pipeline Analysis
    • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Target
    • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Route of Administration
    • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Molecule Type
    • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action
  • Hyundai Pharmaceutical Co Ltd - Dormant Projects
  • Hyundai Pharmaceutical Co Ltd - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Hyundai Pharmaceutical Co Ltd, Key Facts
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Indication, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016
  • Hyundai Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016
  • Hyundai Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016
  • Hyundai Pharmaceutical Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • Hyundai Pharmaceutical Co Ltd - Phase III, 2016
  • Hyundai Pharmaceutical Co Ltd - Phase II, 2016
  • Hyundai Pharmaceutical Co Ltd - Phase I, 2016
  • Hyundai Pharmaceutical Co Ltd - Preclinical, 2016
  • Hyundai Pharmaceutical Co Ltd - Discovery, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Target, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action, 2016
  • Hyundai Pharmaceutical Co Ltd - Dormant Developmental Projects,2016

List of Figures

  • Hyundai Pharmaceutical Co Ltd - Pipeline by Top 10 Indication, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016
  • Hyundai Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016
  • Hyundai Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Top 10 Target, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top